Literature DB >> 11169454

Cervical cancer vaccines: emerging concepts and developments.

D M Da Silva1, G L Eiben, S C Fausch, M T Wakabayashi, M P Rudolf, M P Velders, W M Kast.   

Abstract

Certain human cancers are linked to infection by oncogenic viruses that are able to cause transformation of the normal host cell into a cancerous cell. Human papillomavirus (HPV) DNA and expression of viral transforming proteins are found in virtually all cervical cancer cells, indicating an important role of this virus in the pathogenesis of the disease. Evidence exists that the immune response to cancer cells can play a major role in determining the outcome of disease. The fact that HPV is a necessary cause for cervical cancer provides a clear opportunity to develop a therapeutic vaccine against the virus to treat patients with cervical cancer at its early and late stages. Development of a prophylactic vaccine for HPV would also reduce the incidence of cervical neoplasias by preventing virus infection. Various candidate HPV vaccines are being developed and tested in animal models and/or in human clinical trials. These HPV vaccines, both preventive and therapeutic, are the subjects of this review. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11169454     DOI: 10.1002/1097-4652(200102)186:2<169::AID-JCP1023>3.0.CO;2-H

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  11 in total

Review 1.  [Prophylactic and therapeutic HPV immunization].

Authors:  M Müller; L Gissmann
Journal:  Hautarzt       Date:  2007-06       Impact factor: 0.751

2.  Cancer of the cervix - from bleak past to bright future; a review, with an emphasis on cancer of the cervix in malaysia.

Authors:  Othman Nor Hayati
Journal:  Malays J Med Sci       Date:  2003-01

3.  Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.

Authors:  Peter Ohlschläger; Wolfram Osen; Kerstin Dell; Stefan Faath; Robert L Garcea; Ingrid Jochmus; Martin Müller; Michael Pawlita; Klaus Schäfer; Peter Sehr; Caroline Staib; Gerd Sutter; Lutz Gissmann
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

4.  Induction of immune responses against human papillomaviruses by hypervariable epitope constructs.

Authors:  K Jyotsna Reddy; Babak Banapour; David E Anderson; Sang H Lee; Juan P Marquez; Maria P Carlos; Jose V Torres
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

5.  Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papillomas and infection.

Authors:  Janet L Brandsma; Mark Shlyankevich; Lixin Zhang; Martin D Slade; Edward C Goodwin; Woei Peh; Albert B Deisseroth
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

6.  Immunization and immunotherapy for cancers involving infection by a human papillomavirus in a mouse model.

Authors:  Jin Li; Ying Sun; Alan Garen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-21       Impact factor: 11.205

7.  A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection.

Authors:  Olivia C Demurtas; Silvia Massa; Paola Ferrante; Aldo Venuti; Rosella Franconi; Giovanni Giuliano
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

8.  HPVMD-C: a disease-based mutation database of human papillomavirus in China.

Authors:  Zhenyu Yang; Wenjing Yi; Jin Tao; Xiaoqing Liu; Michael Q Zhang; Guiqian Chen; Qi Dai
Journal:  Database (Oxford)       Date:  2022-03-26       Impact factor: 4.462

9.  Cost-effectiveness of a potential vaccine for human papillomavirus.

Authors:  Gillian D Sanders; Al V Taira
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

10.  Eradication of cervical cancer in vivo by an AAV vector that encodes shRNA targeting human papillomavirus type 16 E6/E7.

Authors:  Naoto Sato; Yasushi Saga; Ryosuke Uchibori; Tomonori Tsukahara; Masashi Urabe; Akihiro Kume; Hiroyuki Fujiwara; Mitsuaki Suzuki; Keiya Ozawa; Hiroaki Mizukami
Journal:  Int J Oncol       Date:  2018-01-15       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.